Role of adjuvant chemoradiotherapy and chemotherapy in patients with resected gallbladder carcinoma: a multiinstitutional analysis (KROG 19-04)

作     者：Sung Uk Lee Jinsil Seong Tae Hyun Kim Jung Ho Im Woo Chul Kim Kyubo Kim Hae Jin Park Tae Gyu Kim Youngkyong Kim Bae Kwon Jeong Jin Hee Kim Byoung Hyuck Kim Taek-Keun Nam Sung Uk Lee;Jinsil Seong;Tae Hyun Kim;Jung Ho Im;Woo Chul Kim;Kyubo Kim;Hae Jin Park;Tae Gyu Kim;Youngkyong Kim;Bae Kwon Jeong;Jin Hee Kim;Byoung Hyuck Kim;Taek-Keun Nam

作者机构：Center for Proton Therapy and Center for Liver and Pancreatobiliary CancerNational Cancer CenterGoyang 10408Korea Department of Radiation OncologyYonsei Cancer CenterYonsei University College of MedicineSeoul 03722Korea Department of Radiation OncologyCHA Bundang Medical CenterCHA University School of MedicineSeongnam 13497Korea Department of Radiation OncologyInha University HospitalInha University School of MedicineIncheon 22332Korea Department of Radiation OncologyEwha Womans University Mokdong HospitalEwha Womans University College of MedicineSeoul 07985Korea Department of Radiation OncologyHanyang University Medical CenterHanyang University College of MedicineSeoul 04763Korea Department of Radiation OncologySamsung Changwon HospitalSungkyunkwan University School of MedicineChangwon 51353Korea Department of Radiation OncologyKyung Hee University HospitalKyung Hee University College of MedicineSeoul 02447Korea Department of Radiation OncologyGyeongsang National University HospitalGyeongsang National University College of MedicineJinju 52727Korea Department of Radiation OncologyDongsan Medical CenterKeimyung University School of MedicineDaegu 41931Korea Department of Radiation OncologySeoul Metropolitan Government Seoul National University Boramae Medical CenterSeoul 07061Korea Department of Radiation OncologyChonnam National University Hwasun HospitalChonnam National University College of MedicineHwasun 58128Korea 

出 版 物：《Cancer Biology & Medicine》 (癌症生物学与医学（英文版）)

年 卷 期：2022年第19卷第6期

页      面：931-944页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：This study was supported by National Cancer Center grants(Grant Nos.NCC 1810271 and 1910300) 

主　　题：Gallbladder cancer adjuvant treatment chemoradiotherapy locoregional recurrence-free survival overall survival 

摘      要：Objective:The effectiveness of adjuvant treatments for resected gallbladder carcinoma(GBC)has remained unclear due to lack of randomized controlled trials;thus,the aim of present study was to evaluate the role of adjuvant treatments,including chemoradiotherapy(CRT)and/or chemotherapy(CTx),in patients with resected ***:A total of 733 GBC patients who received curative-intent surgical resection were identified in a multi-institutional *** 733 patients,372(50.8%)did not receive adjuvant treatment,whereas 215(29.3%)and 146(19.9%)received adjuvant CTx and CRT,*** locoregional recurrence-free survival(LRFS),recurrence-free survival(RFS),and overall survival(OS)of the adjuvant treatment groups were compared according to tumor stage(stage II *** III–IV).Results:In stage II disease(n=381),the 5-year LRFS,RFS,and OS were not significantly different among the no-adjuvant therapy,CTx,and CRT groups,and positive resection margin,presence of perineural invasion,and Nx classification were consistently associated with worse LRFS,RFS,and OS in the multivariate analysis(P0.05).For stage III–IV(n=352),the CRT group had significantly higher 5-year LRFS,RFS,and OS than the no-adjuvant therapy and CTx groups(67.8%,45.2%,and 56.9%;37.9%,28.8%,and 35.4%;and 45.0%,30.0%,and 45.7%,respectively)(P0.05).Conclusions:CRT has value as adjuvant treatment for resected GBC with stage III–IV *** study is needed for stage II disease with high-risk features.